About this policy
CMS NCA document | source_status=Closed | review_type=New | public_comment_open=False | document_id=CAG-00180N
Coverage indications
CMS concludes that there is adequate evidence to determine that the immunoassay fecal occult blood test (iFOBT) is an appropriate and effective colorectal cancer screening fecal occult blood test for Medicare beneficiaries aged 50 years and older. The test appears to have modestly better test performance characteristics and patient compliance compared to existing methods for detecting fecal occult blood. Therefore, CMS intends to issue a positive coverage determination.
Codes in this policy
Code numbers and each code’s status as the policy records it. CPT code descriptions are left out of this page, as are the passages that cite CPT codes; the official document has them.
Backwork has no codes on record for this policy. Check the source.